Suven Life Sciences Limited has informed the Exchange regarding a press release dated September 03, 2026, titled "Suven Life Sciences Announces Completion of Patient Enrollment in Global Phase-3 Study of Masupirdine (SUVN-502) for Agitation Associated with Alzheimer s Dementia (AAD)".
Suven Life Sciences Limited Press Release Sep 03 2026
Earlier from Suven Life Sciences
- Suven Life Sciences: Form MGT 7 FY 2025-2026 (Annual Return)
- Suven Life Sciences Limited Press Release Jul 10 2026
- Suven Life Sciences: July 08, 2026BM outcome 08.07.2026
- Suven Life Sciences Limited Press Release Jun 22 2026